Low Testosterone Screening in Military: Clinical Implications

Military Testosterone Screening: What the Data Actually Show

The Department of Defense's decision to screen older service members for hypogonadism marks a watershed moment in occupational health surveillance. This isn't about performance enhancement—it's about recognizing that systemic testosterone deficiency correlates with increased injury rates, cognitive decline, metabolic dysfunction, and cardiovascular mortality. Understanding the clinical framework matters if you're advising patients or optimizing your own endocrine health.

Why Age Alone Is an Inadequate Screening Criterion

Testosterone naturally declines ~0.5–1% annually after age 30, but this is not linear, and it's not universal. A 55-year-old with total testosterone of 380 ng/dL isn't automatically hypogonadal by pathophysiology—he may be adequately compensated if his free testosterone, SHBG, and symptoms align. The military's move toward screening—rather than waiting for symptomatic presentation—acknowledges that subclinical deficiency accumulates harm before soldiers recognize symptoms.

Key distinction: total testosterone <300 ng/dL is clinically significant in most populations. Free testosterone <9 pg/mL (calculated or measured) is the more sensitive marker for functional hypogonadism, especially in older men where SHBG elevation can mask low bioavailable hormone.

The Endocrine Cascade You Must Understand

Testosterone doesn't exist in isolation. When the hypothalamic-pituitary-gonadal (HPG) axis falters, downstream dysfunction cascades:

• Luteinizing hormone (LH) <2 mIU/mL suggests central hypogonadism (pituitary/hypothalamic origin)
• LH >8 mIU/mL with low-normal testosterone indicates primary testicular failure (Leydig cell insufficiency)
• Elevated SHBG (from liver dysfunction, hyperthyroidism, or aging) artificially suppresses free testosterone while total remains nominally normal

This distinction is critical because treatment pathways diverge: central hypogonadism may respond to GnRH agonists or peptides like gonadorelin; primary testicular failure requires direct testosterone replacement or combination therapy with clomiphene citrate (which preserves the HPG axis and testicular volume).

Screening Protocol: What Should Actually Be Ordered

A responsible low-T screening panel includes:

1. Total testosterone (morning draw, 7–9 AM; afternoon levels are 20–30% lower)
2. Free testosterone (calculated via Vermeulen equation if SHBG is measured; direct measurement via LC-MS preferred)
3. LH and FSH (determines primary vs. secondary hypogonadism)
4. SHBG (critical for interpreting total testosterone in aging men)
5. Estradiol (elevated estradiol can suppress LH and impair erectile function; <50 pg/mL is typical optimal)
6. Prolactin (elevated prolactin suppresses GnRH and reduces LH/FSH)
7. TSH, free T4 (hypothyroidism depresses testosterone synthesis)
8. Fasting glucose, insulin, HbA1c (metabolic syndrome directly correlates with hypogonadism)

Omitting SHBG, LH, or thyroid work creates a blind spot. You cannot interpret a total testosterone of 450 ng/dL without knowing SHBG and free testosterone.

Military Fitness and the Testosterone-Performance Nexus

The military context matters. Hypogonadal soldiers show:

• Slower injury recovery (testosterone drives collagen synthesis and myonuclei accretion)
• Impaired muscle protein synthesis (leucine sensitivity and mTOR activation decline without adequate testosterone)
• Cognitive slowing (testosterone supports dopamine signaling and executive function)
• Increased cardiovascular risk (despite old dogma; modern evidence shows testosterone protective against atherosclerosis at physiologic doses)

A 58-year-old special operations veteran with total testosterone of 320 ng/dL and free testosterone of 6.2 pg/mL is functionally disadvantaged. Screening catches this before accumulating injury or cognitive liability.

Supplementation Synergies for Testosterone Support

If a patient declines pharmaceutical intervention (TRT or peptides), certain supplements support the HPG axis:

• Zinc (25–30 mg/day elemental): Required cofactor for 17β-HSD (converts androstenediol to testosterone). Zinc deficiency impairs LH signaling. Optimal serum zinc: 80–120 μg/dL.
• Vitamin D3 (4,000–5,000 IU/day): Calcitriol acts as transcription factor in Leydig cells. Optimal 25(OH)D: 40–60 ng/mL. Below 30 ng/mL correlates with low-T.
• Magnesium glycinate (300–400 mg/day): Stabilizes SHBG and supports androgen receptor sensitivity. Glycinate form improves absorption and mood.
• Omega-3 (2–3 g EPA/DHA daily): Reduces inflammation; excessive inflammation suppresses testosterone via IL-6 and TNF-α.
• Ashwagandha (600 mg/day, KSM-66 extract): RCT evidence shows ≈15% increase in testosterone in men with low-normal baseline; mechanism is cortisol modulation (high cortisol suppresses GnRH).

These are not replacements for treatment of clinical hypogonadism, but they optimize the environment.

Bottom Line

The military's testosterone screening protocol reflects evidence: subclinical hypogonadism in aging men confers real morbidity. If you're over 45, your baseline testosterone matters. Order the full panel—not just total testosterone. Understand your SHBG and free testosterone. If you're <300 ng/dL total or <9 pg/mL free, discuss pharmacologic options (TRT, clomiphene, or GnRH peptides) with a provider experienced in men's health. Supplements support but don't replace treatment of true deficiency.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.